vs
Side-by-side financial comparison of Caledonia Mining Corp Plc (CMCL) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $46.9M, roughly 1.8× Caledonia Mining Corp Plc). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 7.0%, a 15.8% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 13.8%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 17.1%).
Hochschild Mining plc is a leading British-based silver and gold mining business operating in North, Central, and South America. It is headquartered in Lima, Peru, with a corporate office in London, is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. The main shareholder is the Peruvian businessman Eduardo Hochschild.
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
CMCL vs FDMT — Head-to-Head
Income Statement — Q3 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $46.9M | $85.1M |
| Net Profit | $3.3M | $19.4M |
| Gross Margin | 41.2% | — |
| Operating Margin | 18.6% | 17.3% |
| Net Margin | 7.0% | 22.8% |
| Revenue YoY | 13.8% | 8508900.0% |
| Net Profit YoY | -33.3% | 139.1% |
| EPS (diluted) | $0.13 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $85.1M | ||
| Q3 25 | — | $90.0K | ||
| Q2 25 | — | $15.0K | ||
| Q1 25 | — | $14.0K | ||
| Q4 24 | — | $1.0K | ||
| Q3 24 | $46.9M | $3.0K | ||
| Q2 24 | $50.1M | $5.0K | ||
| Q1 24 | $38.5M | $28.0K |
| Q4 25 | — | $19.4M | ||
| Q3 25 | — | $-56.9M | ||
| Q2 25 | — | $-54.7M | ||
| Q1 25 | — | $-48.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.3M | $-43.8M | ||
| Q2 24 | $10.2M | $-35.0M | ||
| Q1 24 | $2.1M | $-32.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 41.2% | — | ||
| Q2 24 | 45.8% | — | ||
| Q1 24 | 35.9% | — |
| Q4 25 | — | 17.3% | ||
| Q3 25 | — | -67983.3% | ||
| Q2 25 | — | -396373.3% | ||
| Q1 25 | — | -383007.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | 18.6% | -1704400.0% | ||
| Q2 24 | 32.2% | -849120.0% | ||
| Q1 24 | 13.8% | -136200.0% |
| Q4 25 | — | 22.8% | ||
| Q3 25 | — | -63195.6% | ||
| Q2 25 | — | -364386.7% | ||
| Q1 25 | — | -342657.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | 7.0% | -1461433.3% | ||
| Q2 24 | 20.3% | -699060.0% | ||
| Q1 24 | 5.4% | -115717.9% |
| Q4 25 | — | $0.43 | ||
| Q3 25 | — | $-1.01 | ||
| Q2 25 | — | $-0.98 | ||
| Q1 25 | — | $-0.86 | ||
| Q4 24 | — | — | ||
| Q3 24 | $0.13 | $-0.79 | ||
| Q2 24 | $0.42 | $-0.63 | ||
| Q1 24 | $0.07 | $-0.66 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.2M | $402.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $231.0M | $505.7M |
| Total Assets | $339.7M | $566.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $402.7M | ||
| Q3 25 | — | $305.1M | ||
| Q2 25 | — | $293.2M | ||
| Q1 25 | — | $321.4M | ||
| Q4 24 | — | $424.9M | ||
| Q3 24 | $7.2M | $501.9M | ||
| Q2 24 | $15.4M | $541.9M | ||
| Q1 24 | $1.8M | $525.9M |
| Q4 25 | — | $505.7M | ||
| Q3 25 | — | $369.0M | ||
| Q2 25 | — | $420.9M | ||
| Q1 25 | — | $469.7M | ||
| Q4 24 | — | $510.6M | ||
| Q3 24 | $231.0M | $552.9M | ||
| Q2 24 | $231.1M | $588.3M | ||
| Q1 24 | $220.3M | $600.6M |
| Q4 25 | — | $566.7M | ||
| Q3 25 | — | $424.0M | ||
| Q2 25 | — | $473.6M | ||
| Q1 25 | — | $515.7M | ||
| Q4 24 | — | $560.4M | ||
| Q3 24 | $339.7M | $604.0M | ||
| Q2 24 | $338.5M | $620.1M | ||
| Q1 24 | $321.8M | $629.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.6M | $28.6M |
| Free Cash FlowOCF − Capex | — | $28.5M |
| FCF MarginFCF / Revenue | — | 33.5% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | 1.40× | 1.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-109.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $28.6M | ||
| Q3 25 | — | $-46.5M | ||
| Q2 25 | — | $-43.4M | ||
| Q1 25 | — | $-47.8M | ||
| Q4 24 | — | $-134.6M | ||
| Q3 24 | $4.6M | $-29.4M | ||
| Q2 24 | $19.1M | $-30.2M | ||
| Q1 24 | — | $-29.1M |
| Q4 25 | — | $28.5M | ||
| Q3 25 | — | $-46.6M | ||
| Q2 25 | — | $-43.4M | ||
| Q1 25 | — | $-48.4M | ||
| Q4 24 | — | $-138.4M | ||
| Q3 24 | — | $-31.2M | ||
| Q2 24 | — | $-30.6M | ||
| Q1 24 | — | $-29.8M |
| Q4 25 | — | 33.5% | ||
| Q3 25 | — | -51765.6% | ||
| Q2 25 | — | -289620.0% | ||
| Q1 25 | — | -345635.7% | ||
| Q4 24 | — | -13837100.0% | ||
| Q3 24 | — | -1038966.7% | ||
| Q2 24 | — | -611840.0% | ||
| Q1 24 | — | -106421.4% |
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 101.1% | ||
| Q2 25 | — | 440.0% | ||
| Q1 25 | — | 4507.1% | ||
| Q4 24 | — | 378600.0% | ||
| Q3 24 | — | 59266.7% | ||
| Q2 24 | — | 6980.0% | ||
| Q1 24 | — | 2535.7% |
| Q4 25 | — | 1.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.40× | — | ||
| Q2 24 | 1.87× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
